NKG 2A targeting therapy - Servier
Latest Information Update: 30 Nov 2021
At a glance
- Originator Servier
- Class Antineoplastics
- Mechanism of Action NK cell lectin-like receptor subfamily C antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 23 Nov 2021 NKG 2A targeting therapy - Servier is available for licensing as of 18 Nov 2021. https://servier.com/en/areas-of-expertise/partnering/
- 18 Nov 2021 Phase-I clinical trials in Solid tumours in France (unspecified route) before November 2021 (Servire pipeline, November 2021)